NCT02525302 - HT-100 Long-term Study in DMD Patients Who Completed HALO-DMD-02 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

December 30, 2016

Study Completion Date

December 30, 2016

Conditions

Duchenne Muscular Dystrophy

Interventions

DRUG

HT-100

HT-100 is Akashi Therapeutics' proprietary delayed-release formulation of halofuginone hydrobromide, a small molecule therapeutic with anti-fibrotic properties. May be administered in either fed or fasted state. Not mutation specific.

Trial Locations (5)

21205

Kennedy Krieger Institute, Johns Hopkins School of Medicine, Baltimore

43205

Nationwide Children's Hospital, Columbus

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

63110

Washington University School of Medicine, St Louis

95817

University of California, Davis Medical Center, Sacramento